Amivas - Artesunate Injection for Severe Malaria
A Severe Malaria Treatment, Vital for the US Healthcare Community. No FDA-approved injectable malaria medication has been available in the US since IV quinidine was discontinued in early 2019. Artesunate for Injection fills this need.
-
Most popular related searches
Benefits
- Artesunate for Injection is recommended by the WHO as first-line treatment for severe malaria and has been used extensively around the world for more than 20 years.
- The CDC recommends Artesunate for Injection for all patients with severe malaria, regardless of the infecting species of malaria parasite, and has provided Artesunate for Injection on a compassionate use basis from the US Army.
- Artesunate for Injection is appropriate for adults and children. Clinical studies of Artesunate for Injection did not include sufficient patients 65 years of age and older to determine whether they respond differently than younger patients.
Symptoms of the disease can vary widely but severe malaria typically includes neurologic symptoms, severe anemia (hemoglobin level < 70 g/L), hyperparasitemia (> 5%), acute renal injury, acute respiratory distress syndrome, or jaundice.1-3
Severe malaria causes an estimated 405,000 deaths annually around the world, the majority of them in young children.4
In the US, approximately 15% of cases are severe.5,6
Most of these are acquired through travel to malaria-endemic countries.
Rapid-acting artemisinin derivatives such as Artesunate for Injection offers patients and healthcare providers an important therapy.
- Artesunate for Injection is associated with up to a 34.7% reduction in risk of mortality compared with quinine.7,8
- Supplied as a sterile powder, Artesunate for Injection can be safely stored at room temperature.
- Artesunate for Injection is easily constituted in one step.
- View and download Artesunate for Injection dosing information here.
Customer reviews
No reviews were found for Amivas - Artesunate Injection for Severe Malaria. Be the first to review!